• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

反常性银屑病。

Paradoxical Psoriasis.

机构信息

School of Medicine, Royal College of Surgeons in Ireland, Building No. 2441, Road 2835, Busaiteen 228, Bahrain.

Yale College, New Haven, CT, USA.

出版信息

Dermatol Clin. 2024 Jul;42(3):471-480. doi: 10.1016/j.det.2024.02.011. Epub 2024 Apr 10.

DOI:10.1016/j.det.2024.02.011
PMID:38796276
Abstract

Cytokine blocking therapies have revolutionized the management of psoriasis and atopic dermatitis but can lead to the development of paradoxic psoriasis (PP). Patients treated with biologics should be closely monitored for the development of PP and other paradoxical eruptions (including inflammatory joint disease, inflammatory bowel disease, eczematous eruptions, lupus like eruptions, sarcoidal eruptions, and others) and occasionally the development of cutaneous T-cell lymphoma. Further understanding the immunologic mechanism of these processes will ultimately drive our understanding of and ability to predict and manage PPs.

摘要

细胞因子阻断疗法彻底改变了银屑病和特应性皮炎的治疗方法,但也可能导致出现矛盾性银屑病(PP)。使用生物制剂治疗的患者应密切监测 PP 及其他矛盾性发疹(包括炎症性关节病、炎症性肠病、湿疹样发疹、狼疮样发疹、类肉瘤样发疹等)和偶尔出现的皮肤 T 细胞淋巴瘤的发展情况。进一步了解这些过程的免疫机制将最终推动我们对 PP 的认识和预测及管理能力。

相似文献

1
Paradoxical Psoriasis.反常性银屑病。
Dermatol Clin. 2024 Jul;42(3):471-480. doi: 10.1016/j.det.2024.02.011. Epub 2024 Apr 10.
2
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis.皮肤科靶向治疗的矛盾性发作:系统回顾与分析。
J Am Acad Dermatol. 2022 May;86(5):1080-1091. doi: 10.1016/j.jaad.2020.12.010. Epub 2020 Dec 8.
3
Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis.生物制剂诱导的银屑病和特应性皮炎患者免疫表型交叉转换
Indian J Dermatol. 2023 Mar-Apr;68(2):186-191. doi: 10.4103/ijd.ijd_871_22.
4
Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases.变应性和免疫性皮肤疾病中的生物制剂和小分子药物。
Curr Allergy Asthma Rep. 2018 Aug 31;18(10):55. doi: 10.1007/s11882-018-0804-8.
5
Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis.特应性皮炎患者使用特拉喹单抗后出现矛盾性银屑病。
J Dermatolog Treat. 2023 Dec;34(1):2258240. doi: 10.1080/09546634.2023.2258240.
6
Paradoxical eruption exclusively located on the ear in patients with psoriasis treated with biologics: a case series.生物制剂治疗的银屑病患者耳部出现的矛盾性皮疹:病例系列
Clin Exp Dermatol. 2024 Jul 19;49(8):899-901. doi: 10.1093/ced/llae054.
7
Dermatological complications of therapy with biologics in inflammatory autoimmune diseases.炎症性自身免疫性疾病生物制剂治疗的皮肤并发症。
J Dtsch Dermatol Ges. 2019 Oct;17(10):1029-1037. doi: 10.1111/ddg.13964.
8
Concurrent Atopic Dermatitis and Psoriasis Vulgaris: Implications for Targeted Biologic Therapy.特应性皮炎与寻常型银屑病共病:对靶向生物治疗的影响。
Cutis. 2022 Feb;109(2):110-112. doi: 10.12788/cutis.0453.
9
Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.阿达木单抗诱导的银屑病在患有化脓性汗腺炎的患者中针对 IL-17/IL-23 轴的生物制剂治疗的疗效观察。
Dermatology. 2023;239(6):937-941. doi: 10.1159/000533370. Epub 2023 Aug 14.
10
Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?抗肿瘤坏死因子 α 治疗与新发银屑病风险增加:这真的是一种矛盾的副作用吗?
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):700-6. Epub 2012 Oct 17.

引用本文的文献

1
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.曲罗芦单抗作为特应性皮炎中与度普利尤单抗相关的关节痛的治疗替代方案:一项多中心病例系列研究
J Clin Aesthet Dermatol. 2025 May 1;18(5):16-19.
2
Awareness of the Risk of Paradoxical Psoriasis in Patients with SAPHO Syndrome Undergoing Treatment with Secukinumab: A Case Series.司库奇尤单抗治疗SAPHO综合征患者时发生反常性银屑病风险的认识:病例系列
J Inflamm Res. 2025 Mar 12;18:3705-3712. doi: 10.2147/JIR.S510006. eCollection 2025.